Program

› 8:30 am  Welcome

› 8:50 am  Introduction
Christian Boitard, Director ITMO Pathophysiology Metabolism Nutrition

SESSION 1: PATHOPHYSIOLOGICAL BASIS OF MYOCARDIAL ALTERATION
Chairs: Jérémy Fauconnier, Montpellier - Xavier Prieur, Nantes - Bart Staels, Lille

› 9:00 am  Role of EPAC1 in diabetic cardiomyopathy - Frank Lezoualc'h, Toulouse

› 9:15 am  Disruption of reticulum-mitochondria contact sites in metabolic diseases: from type 2 diabetes to diabetic cardiomyopathy - Jennifer Rieusset, Lyon

› 9:30 am  NAD metabolism and signaling in heart diseases - Mathias Mericskay, Chatenay Malabry

› 9:45 am  Myocardial metabolic remodeling and protective role of AMPK - Luc Bertrand, Bruxelles

› 10:00 am  Joint Discussion

› 10:15 am  Coffee Break

SESSION 2: ENVIRONMENT AND DIABETES
Chairs: Hélène Duez, Lille - Bénédicte Gaborit, Marseille - Nicolas Venteclef, Paris

› 10:30 am  Impact of obesity and fat tissue - Maria Pini, Créteil

› 10:50 am  Impact of immunity and microbiota - Agnès Lehuen, Paris

› 11:10 am  Keynote lecture
Metabolism and cell senescence - Elizabeth Blackburn, San Francisco

› 11:45 am  Joint Discussion

› 12:00 pm  Lunch break - Posters visit
SESSION 3: WHICH CLINICAL PHENOTYPING?

Chairs: Monique Bernard, Marseille - Geneviève Derumeaux, Créteil
Samy Hadjadj, Nantes

- 2:00 pm Cardiac imaging options to study DCM - Jan D'hooge, Leuven
- 2:15 pm Microvascular dysfunction in diabetes related heart failure - Chim Lang, Dundee
- 2:30 pm Ultrafast UltraSound Imaging - Mickael Tanter, Paris
- 2:45 pm Metabolomics for clinical phenotyping - Christophe Junot, Saclay
- 3:00 pm Joint Discussion
- 3:15 pm Moderated Poster Discussion
  Discussants: Fabrizio Andreelli, Paris - Marion Laudette, Toulouse -
  David Montaigne, Lille - Laetitia Pereira, Châtenay Malabry

SESSION 4: DIABETIC CARDIOMYOPATHY EVOLUTIVITY

Chairs: Philip Janiak, Chilly Mazarin - Michel Marre, Paris -
Dominique Valla, Paris

- 4:30 pm Health trajectories: Sleep apnea as a user case - Jean-Louis
  Pépin, Grenoble
- 4:45 pm Patterns of comorbidities in type 2 diabetes - Corneliu Henegar,
  Créteil
- 5:00 pm Endothelial dysfunction in HFpEF - Thierry Couffinhal, Bordeaux
- 5:15 pm Joint Discussion
- 5:30 pm Conclusion: Geneviève Derumeaux, Network coordinator